Rosacea
Conditions
Brief summary
To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment
Interventions
DRUGAzelaic Acid (Finacea Foam, BAY39-6251)
Finacea Foam, Active substance Azelaic acid
Sponsors
Bayer
LEO Pharma
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 18 years of age * Diagnosis of rosacea by a medical professional * Currently using Finacea Foam as topical monotherapy for rosacea * Willing and able to provide voluntary, informed consent to participate in this study
Exclusion criteria
\- Use of any other topical treatment for rosacea at the time of enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographics and clinical characteristics | one-time survey in 2 week recruitment window | Collected patient demographics and characteristics are : * Year of birth * Gender * Insurance type |
| Rosacea-relevant comorbidities and complications | one-time survey in 2 week recruitment window | Patient reported history of the following will be collected : * Blepharitis * Conjunctivitis * Corneal neovascularization/keratitis * Depression * Migraine |
| Rosacea subtype | one-time survey in 2 week recruitment window | Patient reported diagnosis of the following will be collected: * Erythematotelangiectatic (facial redness) * Papulopustular (bumps and pimples) * Phymatous (enlargement of the nose) * Ocular (eye irritation) * Unknown |
| Past use of topical rosacea treatments | one-time survey in 2 week recruitment window | Patient reported use of the following medications will be collected: * Metronidazole gel * Metronidazole cream * Metronidazole lotion * Metronidazole emulsion * Brimonidine tartrate gel |
| Patient concerns collected by Rosacea Treatment Preference Questionnaire | one-time survey in 2 week recruitment window | Rosacea Treatment Preference Questionnaire is a survey to assess patient self-reported rosacea subtype and severity, and to evaluate the concerns that contribute to patient satisfaction/dissatisfaction, as well as treatment decisions with rosacea topical treatments |
| Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q) | one-time survey in 2 week recruitment window | SATMED-Q is a 17-question, validated, multidimensional generic questionnaire designed for use in patients with any chronic disease treated with medicines |
| Quality of life measured by Dermatology Life Quality Index (DLQI) | one-time survey in 2 week recruitment window | DLQI is a widely used dermatology-related quality of life tool |
Countries
United States
Outcome results
None listed